Stock CYTH CYCLO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
1.4 USD +2.19% Intraday chart for Cyclo Therapeutics, Inc. -4.76% -11.95%
05-01 HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target MT
03-18 Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease
Cyclo Therapeutics, Applied Molecular Transport Complete Merger
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1
Cyclo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading
Top Premarket Decliners
Cyclo Therapeutics, Applied Molecular Transport Agree to Merge
Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board
Cyclo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cyclo Therapeutics Says European Patent Office Grants Allowance of Trappsol Cyclo Patent; Shares Rise
Cyclo Therapeutics Signs $5 Million Funding Deal with Rafael Holdings
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director
Insider Buy: Cyclo Therapeutics
Cyclo Therapeutics Says in Preliminary Talks with Potential Strategic Parties
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTH Stock
  4. News Cyclo Therapeutics, Inc.
  5. Other languages